To corroborate their findings, they analyzed data from The Cancer Genome Atlas and REMBRANDT public databases; they found that low expression of LDHA and high methylation of the LDHA promoter was found in IDHmt glioblastoma (GBM) patients and glioma patients whose tumors overexpressed LDHA had a median survival of 16 months, whereas patients whose tumor underexpressed LDHA had a median survival of >50 months 14. This evidence concerns the gene LDHA and neoplasm.